LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Mitoxantrone | 10.0 | uM | LJP6 | 3 | C19 | 72 | hr | 1476 | 455 | 3694 | 0.1232 | -0.4608 |
| SK-BR-3 | MK2206 | 10.0 | uM | LJP6 | 1 | F01 | 72 | hr | 1476 | 1328 | 3694 | 0.3595 | -0.0671 |
| SK-BR-3 | MK2206 | 10.0 | uM | LJP6 | 2 | F01 | 72 | hr | 1476 | 1261 | 3694 | 0.3414 | -0.0973 |
| SK-BR-3 | MK2206 | 10.0 | uM | LJP6 | 3 | F01 | 72 | hr | 1476 | 1438 | 3694 | 0.3893 | -0.0175 |
| SK-BR-3 | Neratinib | 10.0 | uM | LJP5 | 1 | A13 | 72 | hr | 1476 | 1056 | 3694 | 0.2859 | -0.1897 |
| SK-BR-3 | Neratinib | 10.0 | uM | LJP5 | 2 | A13 | 72 | hr | 1476 | 1176 | 3694 | 0.3184 | -0.1356 |
| SK-BR-3 | Neratinib | 10.0 | uM | LJP5 | 3 | A13 | 72 | hr | 1476 | 1008 | 3694 | 0.2729 | -0.2114 |
| SK-BR-3 | Nilotinib | 10.0 | uM | LJP5 | 1 | N13 | 72 | hr | 1476 | 2157 | 3694 | 0.5839 | 0.3068 |
| SK-BR-3 | Nilotinib | 10.0 | uM | LJP5 | 2 | N13 | 72 | hr | 1476 | 1818 | 3694 | 0.4921 | 0.1539 |
| SK-BR-3 | Nilotinib | 10.0 | uM | LJP5 | 3 | N13 | 72 | hr | 1476 | 2040 | 3694 | 0.5522 | 0.2540 |
| SK-BR-3 | Nintedanib | 10.0 | uM | LJP6 | 1 | H01 | 72 | hr | 1476 | 859 | 3694 | 0.2325 | -0.2786 |
| SK-BR-3 | Nintedanib | 10.0 | uM | LJP6 | 2 | H01 | 72 | hr | 1476 | 1143 | 3694 | 0.3094 | -0.1505 |
| SK-BR-3 | Nintedanib | 10.0 | uM | LJP6 | 3 | H01 | 72 | hr | 1476 | 930 | 3694 | 0.2518 | -0.2466 |
| SK-BR-3 | NU7441 | 10.0 | uM | LJP5 | 1 | C07 | 72 | hr | 1476 | 1710 | 3694 | 0.4629 | 0.1052 |
| SK-BR-3 | NU7441 | 10.0 | uM | LJP5 | 2 | C07 | 72 | hr | 1476 | 1811 | 3694 | 0.4903 | 0.1508 |
| SK-BR-3 | NU7441 | 10.0 | uM | LJP5 | 3 | C07 | 72 | hr | 1476 | 1763 | 3694 | 0.4773 | 0.1291 |
| SK-BR-3 | Dactolisib | 10.0 | uM | LJP5 | 1 | M13 | 72 | hr | 1476 | 1543 | 3694 | 0.4177 | 0.0299 |
| SK-BR-3 | Dactolisib | 10.0 | uM | LJP5 | 2 | M13 | 72 | hr | 1476 | 1621 | 3694 | 0.4388 | 0.0651 |
| SK-BR-3 | Dactolisib | 10.0 | uM | LJP5 | 3 | M13 | 72 | hr | 1476 | 1644 | 3694 | 0.4450 | 0.0754 |
| SK-BR-3 | NVP-TAE684 | 10.0 | uM | LJP6 | 1 | K13 | 72 | hr | 1476 | 919 | 3694 | 0.2488 | -0.2515 |
| SK-BR-3 | NVP-TAE684 | 10.0 | uM | LJP6 | 2 | K13 | 72 | hr | 1476 | 1028 | 3694 | 0.2783 | -0.2024 |
| SK-BR-3 | NVP-TAE684 | 10.0 | uM | LJP6 | 3 | K13 | 72 | hr | 1476 | 949 | 3694 | 0.2569 | -0.2380 |
| SK-BR-3 | Palbociclib | 10.0 | uM | LJP6 | 1 | E13 | 72 | hr | 1476 | 2558 | 3694 | 0.6925 | 0.4877 |
| SK-BR-3 | Palbociclib | 10.0 | uM | LJP6 | 2 | E13 | 72 | hr | 1476 | 2591 | 3694 | 0.7014 | 0.5025 |
| SK-BR-3 | Palbociclib | 10.0 | uM | LJP6 | 3 | E13 | 72 | hr | 1476 | 2601 | 3694 | 0.7041 | 0.5070 |